DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service

Food and Drug Administration
Rockville, MD 20857

Our STN: BL 125141/74

Genzyme Corporation
Attention: Cynthia Scott, M.S.
Principal Associate, Regulatory Affairs
500 Kendall Street
Cambridge, MA 02142

Dear Ms. Scott:

Your request to supplement your biologics license application for Myozyme (alglucosidase alfa) to revise the Warnings, Precautions, Adverse Reactions, and Dosage and Administration sections of the labeling has been approved.

Within 21 days of the date of this letter, submit content of labeling [21 CFR 601.14(b)] in structured product labeling (SPL) format, as described at http://www.fda.gov/oc/datacouncil/spl.html, that is identical in content to the enclosed labeling text. Upon receipt, we will transmit that version to the National Library of Medicine for public dissemination. For administrative purposes, please designate this submission "Product Correspondence – Final SPL for approved STN BL 125141/74." In addition, within 21 days of the date of this letter, amend any pending supplement for this BLA with content of labeling in SPL format to include the changes approved in this supplement.

Marketing the product with labeling that is not identical to the approved labeling text may render the product misbranded and an unapproved new drug.

Please refer to http://www.fda.gov/cder/biologics/default.htm for information regarding therapeutic biological products, including the addresses for submissions.

This information will be included in your biologics license application file.

Sincerely,

12/8/08

Donna Griebel, M.D.
Director
Division of Gastroenterology Products
Office of Drug Evaluation III
Center for Drug Evaluation and Research